Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
BICYCLE THERAPEUTICS plc (BCYC) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/03/2023 8-K Quarterly results
Docs: "Bicycle Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update"
07/13/2023 8-K Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Other Events, Financial Statements...
Docs: "Bicycle Therapeutics plc 4,705,884 American Depositary Shares representing 4,705,884 Ordinary Shares, nominal value £0.01 per share 4,705,882 Non-Voting Ordinary Shares, nominal value £0.01 per share",
"Description of the Non-Voting Ordinary Shares",
"Granta Park, Great Abington"
05/26/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Opinion of Cooley (UK) LLP"
05/10/2023 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Bayer and Bicycle Therapeutics Enter Strategic Collaboration for Development of Novel Targeted Radionuclide Therapies in Oncology"
05/04/2023 8-K Quarterly results
04/03/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Bicycle Therapeutics Enhances Leadership Team with Key Appointments"
03/28/2023 8-K Quarterly results
02/28/2023 8-K Quarterly results
Docs: "Bicycle Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update"
02/14/2023 8-K Quarterly results
01/23/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
11/08/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Bicycle Therapeutics Announces First Patient Dosed in BT8009 Phase II Expansion Cohorts and Provides Program Update"
11/03/2022 8-K Quarterly results
09/07/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Media:"
08/04/2022 8-K Quarterly results
Docs: "Bicycle Therapeutics plc Condensed Consolidated Statements of Operations and Comprehensive Loss Three Months Ended Six Months Ended June 30, June 30, 2022 2021 2022 2021 Collaboration revenues $ 4,378 $ 1,785 $ 8,238 $ 3,593 Operating expenses: Research and development 19,854 11,722 34,138 21,415 General and administrative 11,824 7,340 28,783 15,479 Total operating expenses 31,678 19,062 62,921 36,894 Loss from operations Other income : Interest income 908 23 1,126 38 Interest expense Total other income , net 25 Net loss before income tax provision Benefit from income taxes Net loss $ $ $ $ Net loss per share, basic and diluted $ $ $ $ Weighted average ordinary shares outstanding, basic and diluted 29,648,564 24,052,168 29,626,974 23,047,745 Balance Sheets Data June 30, December..."
07/15/2022 8-K Quarterly results
07/12/2022 8-K Quarterly results
06/27/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
04/12/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Bicycle Therapeutics Announces Interim BT8009 Phase I Clinical Trial Results at the 2022 AACR Annual Meeting",
"Presentation"
03/01/2022 8-K Quarterly results
01/05/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Bicycle Therapeutics Announces Continued Clinical Progress and Updates to Management Team"
11/08/2021 8-K Regulation FD Disclosure  Interactive Data
11/04/2021 8-K Quarterly results
Docs: "Bicycle Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update",
"Bicycle Therapeutics Announces First Patient Dosed in Phase I/II Trial of Bicycle® Tumor-targeted Immune Cell Agonist™ BT7480 in Patients with Advanced Solid Tumors Associated with Nectin-4 Expression"
10/26/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Bicycle Therapeutics Announces Expansion of Genentech Immuno-Oncology Collaboration"
10/07/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Bicycle Therapeutics Announces Interim BT5528 Phase I Clinical Trial Results and Preliminary Results from Ongoing BT8009 Phase I Clinical Trial",
"Presentation"
08/05/2021 8-K Quarterly results
Docs: "Bicycle Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update"
07/13/2021 8-K Quarterly results
06/28/2021 8-K Quarterly results
05/24/2021 8-K Quarterly results
05/06/2021 8-K Quarterly results
04/09/2021 8-K Quarterly results
04/02/2021 8-K Quarterly results
03/19/2021 8-K Quarterly results
03/16/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy